anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A therapeutic or preventive agent for nausea/vomiting which contains as an active ingredient either a morphinane derivative represented by the general formula (I): (I) (wherein R1 represents cyclopropylmethyl, etc.; R2 and R3 each represents hydroxy, methoxy, etc.; R4 and R5 are bonded to each other to form -O-, etc.; R6 represents hydrogen, etc.; and Q represents (II) which has been optionally substituted, etc., provided that X represents NH, NMe, etc.) or a pharmacologically acceptable acid addition salt thereof. The compound or salt is useful in a medicine widely applicable to vomiting caused by drugs having emetic activity, especially in a therapeutic or preventive agent for nausea/vomiting induced by µ agonists represented by morphine.
The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of an siRNA that inhibits expression of REG4 or KIAA0101. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumor cell, for example pancreatic cancer cell, prostatic cancer cell, breast cancer cell, and bladder cancer cell, particularly pancreatic ductal adenocarcinoma (PDAC) by inhibiting REG4 gene. The present invention also relates to methods of treating or preventing PDAC in a subject comprising the step of administering to said subject a pharmaceutically effective amount of an antibody or fragment thereof that binds to a protein encoded by REG4. The present invention also relates to methods of diagnosing chemo-radiation therapeutic resistance of a cancer. The present invention also provides therapeutic agents or methods for treating cancer using the polypeptides. The polypeptides of the present invention are composed of an amino acid sequence which comprises polypeptide which comprises QKGIGEFF/SEQ ID NO: 21. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine.
Ras mutant unresectable CRLM patients with primary tumor resection followed by avastin in combination with chemotherapy were included in this study. The tumor response was assessed by local MDT group. Based on tumor response, 58 CRLM patients were classified into two groups (CR+PR vs SD+PD). Primary samples of the two group patients will be sequenced by mass spectrum. After MS sequencing, a prediction model will be estimated. Another 58 CRLM patients will be inclued for validation of the prediction model.
With total hip replacement surgery, the orthopaedic surgeon's aim is not only pain relief for the patient, but also restoration of hip joint biomechanics resulting in a minimal functional deficit and maximal longevity of the implant. It is not exceptional that these patients still experience mild to moderate long-term impairments postoperatively. These impairments include pain, muscle weakness of the hip abductors, contracture of the hip, gait disorders, as well as weakness of hip extensors and flexors. These problems may in turn lead to complications such as joint instability and loosening of the implant. When the lateral surgical approach is used, major concerns after total hip replacement surgery are muscle abductor weakness/atrophy, tendon defects of the gluteus minimus muscle, and unsuccessful reattachment or denervation of the anterior gluteal flap.

Minimal incision/invasive surgery (MIS) is defined as a surgical approach performed through a short skin and muscle incision to avoid injury to muscles and tendons. Following minimally invasive approach reduced muscle trauma has been found. Moreover clinical outcome improved, as the gluteus medius muscle can be spared more successfully. However, it is debated whether or not the overall results of MIS are superior, or even as good as the traditional hip replacement surgery in terms of component placing and time to revision of the prosthesis.
1. A method for raising an immune response in a human or animal host, wherein said method comprising transducing cells of a lymphoid organ or cells which migrate to a lymphoid organ, a genetic construct which encodes a virus such that said cell expresses said virus in a lymphoid organ of said host. 2. The method, according to Claim 1, wherein said cells are dendritic cells. 3. The method, according to Claim 1, wherein said virus is integration-defective or replication-incompetent and is not able to cause a disease in a host with immunodeficiency. 4. The method, according to Claim 2, wherein said virus has an incomplete integrase gene, wherein said integrase is mutated in the active site and in the DNA binding site. 5. The method, according to Claim 3, wherein said virus has a mutation in the gag gene. 6. The method, according to any of preceding claims, wherein said virus is a retrovirus or a lentivirus. 7. The method, according to Claim 6, wherein said virus is selected from the group consisting of HIV-1, HIV-2, SIV, HTLV-1, and FIV. 8. The method, according to Claim 3, wherein said virus is a canary pox virus. 9. The method, according to any of preceding claims, which further comprises transducing a cell with a genetic construct to express a cytokine. 10. The method, according to Claim 9, wherein said cytokine is selected from the group consisting of IL-1, IL-2, IL-3, IL 4, IL-6, IL-7, IL-12, IL-15, IL-16, TNF, GM-CSF, IFN, and chemokines of RANTES, M1P1. 11. The method, according to any of Claims 9 or 10, wherein the expression of said cytokine stimulates a Th1 or Th2 type immune response or a natural killer cell response, or cytotoxic T-cell response, or a B-cell response. 12. The method, according to any of preceding claims, further comprises transducing a cell with a genetic construct to express a tumor antigen. 13. The method, according to Claim 12, wherein said tumor antigen is selected from the group consisting of MAGE-1 antigens, p21ras, human papillomavirus E6 and E7 gene products , and mutants of these proteins. 14. The method, according to any of preceding claims, which is used to alleviate or prevent a cancerous condition. 15. The method, according to any of preceding claims, wherein the immune response is cross-protective.
This invention relates to a method of producing peracetyloxazolines from peracetyl saccharides. The method involves reacting the starting material, a peracetyl saccharide, with a reagent combination, to directly produce the peracetyl oxazoline. This method maybe used for the activation of oligosaccharides, wherein an oligosaccharide containing a reducing GIcNAc terminus is activated by the formation of an oxazoline at the terminal GIcNAc, and then coupled with a bifunctional spacer to provide an oli-gosaccharide-spacer conjugate. The activated oligosaccharide-spacer conjugate is then coupled to a protein, such as granulocyte colony stimulating factor or .gamma.-interferon, providing a neoglycoprotein conjugate. The invention provides a method for forming neoglycoprotein conjugates which may improve biological and physiochemical properties of the protein. For example, serum life-time or efficiency of drug delivery of the peptide to a target organ or cell may be improved.
Participants in the WLC will continue with their regular treatments for the 12 week study period but not receive any study related intervention during this 12 weeks. Following completion of all study assessments WLC participants will self-select either SSIPP or PST. Participants in WLC will not complete study assessments after week 12.
The invention belongs to the scientific technical fields of biology, medicine and medical instruments. Hemorrhoid is a unique common illness and frequently occurring illness of humans, which is not life-threatening, but severely affects survival quality, and brings various inconvenience to learning, working and living of patients. Currently, surgery treatment is a main method for treating the hemorrhoid by Western medicine, but the method usually causes bleeding, pains, swelling, edema, dysuria and other complications, even severe infection, and has a certain limitation and higher treatment expense. Until now, no effective method for conservative treatment is found in the Western medicine. In the invention, local fork medicaments are adopted as main drugs, and a modern pharmacy process is applied to prepare a compound rehmannia hemorrhoid eliminating ointment with convenience in use. Results in 240 cases of clinical observation on patients with internal hemorrhoids, external hemorrhoids and mixed hemorrhoid indicate that: the total effect of a treatment group reaches 96.88 percent which is superior to a contrast group. The compound rehmannia hemorrhoid eliminating ointment has remarkable curative effects on hematochezia, anus pain, pruritus and other symptoms.
The present invention relates to a method for producing soap based on citrus peels, leaves of Sasa borealis (Hack.) Makino, Gynura Procumbens and Allium microdictyon Prokh and having excellent skin cosmetic effects. The method according to the present invention comprises the steps of: mixing and heating juice of citrus peels, dry powder of citrus peels and a soap base, cooling the mixture, and cutting the mixture into pellets having a predetermined size to provide pellets of citrus peel soap; mixing and heating dry powder of Gynura Procumbens, dry powder of leaves of Sasa borealis (Hack.) Makino, an extract of leaves of Sasa borealis (Hack.) Makino and a soap base, cooling the mixture, and cutting the mixture into pellets having a predetermined size to provide pellets of Gynura Procumbens soap; mixing and heating dry powder of Allium microdictyon Prokh, an extract of leaves of Sasa borealis (Hack.) Makino and a soap base, cooling the mixture, and cutting the mixture into pellets having a predetermined size to provide pellets of Allium microdictyon Prokh soap; mixing heated and molten soap base with the pellets of citrus peel soap, pellets of Gynura Procumbens soap, pellets of Allium microdictyon Prokh soap, an extract of leaves of Sasa borealis (Hack.) Makino and juice of citrus peels, and curing the mixture to finish soap.
OBJECTIVE: Sepsis-induced coagulopathy (SIC) is extremely common in individuals with sepsis, significantly associated with poor outcomes. This study attempted to develop an interpretable and generalizable machine learning (ML) model for early predicting the risk of 28-day death in patients with SIC.
METHODS: In this retrospective cohort study, we extracted SIC patients from the Medical Information Mart for Intensive Care III (MIMIC-III), MIMIC-IV, and eICU-CRD database according to Toshiaki Iba's scale. And the overlapping in the MIMIC-IV was excluded for this study. Afterward, only the MIMIC-III cohort was randomly divided into the training set, and the internal validation set according to the ratio of 7:3, while the MIMIC-IV and eICU-CRD databases were considered the external validation sets. The predictive factors for 28-day mortality of SIC patients were determined using recursive feature elimination combined with tenfold cross-validation (RFECV). Then, we constructed models using ML algorithms. Multiple metrics were used for evaluation of performance of the models, including the area under the receiver operating characteristic curve (AUROC), area under the precision recall curve (AUPRC), accuracy, sensitivity, specificity, negative predictive value, positive predictive value, recall, and F1 score. Finally, Shapley Additive Explanations (SHAP), Local Interpretable Model-Agnostic Explanations (LIME) were employed to provide a reasonable interpretation for the prediction results.
RESULTS: A total of 3280, 2798, and 1668 SIC patients were screened from MIMIC-III, MIMIC-IV, and eICU-CRD databases, respectively. Seventeen features were selected to construct ML prediction models. XGBoost had the best performance in predicting the 28-day mortality of SIC patients, with AUC of 0.828, 0.913 and 0.923, the AUPRC of 0.807, 0.796 and 0.921, the accuracy of 0.785, 0.885 and 0.891, the F1 scores were 0.63, 0.69 and 0.70 in MIMIC-III (internal validation set), MIMIC-IV, and eICU-CRD databases. The importance ranking and SHAP analyses showed that initial SOFA score, red blood cell distribution width (RDW), and age were the top three critical features in the XGBoost model.
CONCLUSIONS: We developed an optimal and explainable ML model to predict the risk of 28-day death of SIC patients 28-day death risk. Compared with conventional scoring systems, the XGBoost model performed better. The model established will have the potential to improve the level of clinical practice for SIC patients.
Morbidly obese subjects who will undergo sleeve gastrectomy. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated \~ 9 months after surgery.
Proleukin® (aldesleukin) is supplied in individually boxed single-dose vials. Each vial contains 22 million International Units of Proleukin. Discard unused portion.

NDC 65483-116-07 Individually boxed single-dose vial

Store vials of lyophilized Proleukin in a refrigerator at 2° to 8°C (36° to 46°F). PROTECT FROM LIGHT. Store in carton until time of use.

Reconstituted or diluted Proleukin is stable for up to 48 hours at refrigerated and room temperatures, 2° to 25°C (36° to 77°F). However, since this product contains no preservative, the reconstituted and diluted solutions should be stored in the refrigerator.

Do not use beyond the expiration date printed on the vial. NOTE: This product contains no preservative.

Rx Only
The participants will undergo a full-body resistance training protocol with high repetitions (15+), low load (\<60% of 1RM), and short rest between sets (30s). Training will be undertaken three times per week.
Patients undergo GA before lymphodepleting chemotherapy and recommendations based on assessment results communicated to treating physicians. Patients receive PT and delirium prevention education prior to lymphodepletion, at least once before CAR-T therapy, at least 2 times a week while inpatient, and at least once every other week outpatient up to day 30. Additionally, patients receive personalized nutritional guidance from a registered dietician prior to lymphodepletion, prior to CAR-T therapy and at least once a week up to day 30.
BACKGROUND: Backward walking is an indispensable component of activities of daily living. The backward walk test has been used to assess balance, mobility, and fall risk in different populations. This systematic review aimed to identify and synthesize measurement properties of the backward walk test in people with balance and mobility deficits.
METHODS: Three bibliographic databases, PubMed, Embase, and Scopus, were searched on June 18th, 2023. Cross-sectional or cohort studies assessing the measurement properties (reliability, validity, responsiveness) of the backward walk test were included. The COSMIN risk of bias checklist was used for methodological quality assessment. Study selection, data extraction, and quality assessment were completed by two reviewers independently and in duplicate.
RESULTS: A total of 786 records were identified from three databases. Fourteen studies published from 2019 to 2023 with a total of 853 participants were included. Two studies were rated inadequate in quality assessment, all other studies demonstrated adequate to very good quality. The participants population included patients with cerebral palsy, stroke, multiple sclerosis, Parkinson's disease, fibromyalgia, hip and knee arthroplasty, dementia, and community-dwelling older adults. Good interrater and intrarater reliability, and moderate to good concurrent validity of the backward walk test were demonstrated.
SIGNIFICANCE: The review demonstrates that the backward walk test appears to be a valid and reliable tool in different patient populations. The 3-meter backward walk time and 3-meter backward walk speed can be used as outcome measures in clinical practice to assess balance and mobility and track progress throughout the course of physical rehabilitation. Future studies with a prospective cohort design are required to provide information regarding the predictive validity of the backward walk test for fall risk assessment.
The present invention discloses virus resistant fusion protein, a coding gene and application thereof. The virus resistant fusion protein of the present invention has one of the following amino acid residue sequences: 1) SEQ ID No. 1 in a sequence table; 2) the virus resistant fusion protein is characterized in that the amino acid residue sequence of the SEQ ID No. 1 in the sequence table is replaced, deleted and/or added by one or a plurality of amino acid residues and is used for degrading HIV viral RNA. The fusion protein has an obvious inhibiting function for HIV virus infection. The fusion protein can be used for preparing medicine for preventing and/or treating Aids.
Relieving postoperative nephrectomy pain requires multimodal approaches. The most commonly used in the treatment of pain are nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and infiltration of local anesthetics. Due to the side effects of NSAIDs and opioids, the application of regional analgesia techniques can reduce complications while providing better analgesia quality. Peripheral blocks such as ESP block and M-TAPA block and multimodal analgesics reduce side effects by reducing the use of other analgesics. Pain is considered one of the most important factors affecting the quality of healing. Postoperative pain delays the postanesthesia care unit, hospital stay, early ambulation, increases resource utilization, and negatively affects patient satisfaction. If postoperative analgesia is provided, all these negativities will be eliminated. This study aimed to compare the effectiveness of erector spinae plane block (ESP block) and modified thoracoabdominal nerve blocking with perichondrial approach (M-TAPA block) in postoperative analgesia management in nephrectomy cases.
Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
Estrogen is a hormone that activates bone-forming cells and prevents calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may accelerate bone breakdown and inhibit the body's ability to create new bone, thereby leading to bone loss and possibly osteoporosis. Various treatments have been developed to decrease bone loss in post-menopausal women. Actonel, for example, is an FDA-approved drug used to help prevent bone loss.

Phytoestrogens are plant compounds with a structure similar to estrogen. They have also been shown to help reduce the negative effects of menopause. Isoflavones are a particular type of phytoestrogens that are found in soy plants and may act like estrogen in providing possible protection against bone loss. This study will compare the effects of isoflavones (including genistein, a type of isoflavone) versus Actonel on calcium absorption and bone loss in post-menopausal women.

Participants in this double-blind cross-over study will first complete a screening process, which will include answering questions about their health habits, medical history, physical activity, and food patterns. They will then eat one soy bar daily for 3 days. On Day 4, a urine sample will be taken to assess their ability to metabolize phytoestrogen from soybeans. Participants will be randomly assigned to a specific treatment order. Participants will receive 1-4 unique soy isoflavones, followed by Actonel. Treatment phases will be separated by a 50-day washout period. All participants will also take calcium and vitamin D supplements throughout the study. Assessments will include bone density measurements, calcium absorption tests, and blood and urine tests. The study will last approximately 2.5 years.
BACKGROUND: Previous observational studies have revealed a potentially robust bidirectional relationship between frailty and low back pain (LBP). However, the precise causal relationship remains unclear.
METHODS: To examine the potential causal association between frailty and LBP, we conducted bidirectional two-sample Mendelian randomization analysis (MR) study. Genetic data on frailty index (FI) and LBP were acquired from publicly available genome-wide association studies (GWAS). Various MR methodologies were utilized, such as inverse variance weighting (IVW), weighted median, and MR-Egger, to evaluate causality. Additionally, sensitivity analyses were conducted to evaluate the robustness of the findings.
RESULTS: Genetically predicted higher FI (IVW, odds ratio [OR] = 1.66, 95% CI 1.17-2.36, p = 4.92E-03) was associated with a higher risk of LBP. As for the reverse direction, genetic liability to LBP showed consistent associations with a higher FI (IVW, OR = 1.13, 95% CI 1.07-1.19, p = 2.67E-05). The outcomes from various MR techniques and sensitivity analyses indicate the robustness of our findings.
CONCLUSION: Our research findings provide additional evidence bolstering the bidirectional causal relationship between frailty and LBP.
Stress can lead to gut dysbiosis in brain-gut axis disordered diseases as irritable bowel syndrome (IBS), yet the mechanisms how stress transfer from the brain to the gut and disrupt gut microbiota remain elusive. Here we describe a stress-responsive brain-to-gut axis which impairs colonocytes' mitochondria to trigger gut dysbiosis. Patients with IBS exhibit significantly increased facultative anaerobes and decreased obligate anaerobes, related to increased serum corticotropin-releasing hormone (CRH) level and defected colonocytes' mitochondria ultrastructure. Mice exposed to acute stress experienced enhanced CRH-CRH receptor type 1 (CRHR1) signaling, which impaired mitochondria and epithelium hypoxia in the colon, subsequently triggered gut dysbiosis. Antagonizing CRHR1 expression to inhibit cAMP/Ras/MAPK signaling or activating mitochondria respiration conferred resilience against stress-induced mitochondria damaging and epithelium hypoxia impairment, ultimately improving gut dysbiosis. These results suggest that the CRH-CRHR1-mitochondria pathway plays a pivotal role in stress-induced gut dysbiosis that could be therapeutically targeted for stress-induced gastrointestinal diseases. Yiming Zhang et.al report that psychological stress activated Corticotropin-releasing hormone (CRH)-CRH receptor type 1 (CRHR1)-mitochondria pathway to trigger gut dysbiosis and reveal CRHR1 upregulation damages mitochondria via cAMP/Ras/MAPK signaling in colonocytes.
Age: minimum of 18 years, Undergoing pancreatic or ENT tumour surgery, Ability to give informed consent, Volunteering to the study. Monitored in addition to standard monitoring using PaMo device.